Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine

The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BIRGITTA OLSSON, JAN STROEMBOM, BENGT HALLEN, LISBETH NILVEBRANT, ANDERS RINGBERG, TORKEL GREN, MARTIN WIKBERG
Format:	Patent
Sprache:	est
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	BIRGITTA OLSSON JAN STROEMBOM BENGT HALLEN LISBETH NILVEBRANT ANDERS RINGBERG TORKEL GREN MARTIN WIKBERG
description	The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EE05191B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EE05191B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EE05191B13</originalsourceid><addsrcrecordid>eNqFyzEOwjAMQNEsDAi4AvIBikSEGFhBqbp0Y68MNZLBiaPavT8d2Jn-8t869C1OGd1odhYuBB_NVY3dWLU0kNnA2FBGfICrOE06Mhdu4I1gJLIQtNkxL3obVi8Uo92vm7Bv0_3WHajqQFbxSYV8SOl4jpd4jae_wxcH3DWb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine</title><source>esp@cenet</source><creator>BIRGITTA OLSSON ; JAN STROEMBOM ; BENGT HALLEN ; LISBETH NILVEBRANT ; ANDERS RINGBERG ; TORKEL GREN ; MARTIN WIKBERG</creator><creatorcontrib>BIRGITTA OLSSON ; JAN STROEMBOM ; BENGT HALLEN ; LISBETH NILVEBRANT ; ANDERS RINGBERG ; TORKEL GREN ; MARTIN WIKBERG</creatorcontrib><description>The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.</description><language>est</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090817&DB=EPODOC&CC=EE&NR=05191B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25551,76304</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090817&DB=EPODOC&CC=EE&NR=05191B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BIRGITTA OLSSON</creatorcontrib><creatorcontrib>JAN STROEMBOM</creatorcontrib><creatorcontrib>BENGT HALLEN</creatorcontrib><creatorcontrib>LISBETH NILVEBRANT</creatorcontrib><creatorcontrib>ANDERS RINGBERG</creatorcontrib><creatorcontrib>TORKEL GREN</creatorcontrib><creatorcontrib>MARTIN WIKBERG</creatorcontrib><title>Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine</title><description>The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFyzEOwjAMQNEsDAi4AvIBikSEGFhBqbp0Y68MNZLBiaPavT8d2Jn-8t869C1OGd1odhYuBB_NVY3dWLU0kNnA2FBGfICrOE06Mhdu4I1gJLIQtNkxL3obVi8Uo92vm7Bv0_3WHajqQFbxSYV8SOl4jpd4jae_wxcH3DWb</recordid><startdate>20090817</startdate><enddate>20090817</enddate><creator>BIRGITTA OLSSON</creator><creator>JAN STROEMBOM</creator><creator>BENGT HALLEN</creator><creator>LISBETH NILVEBRANT</creator><creator>ANDERS RINGBERG</creator><creator>TORKEL GREN</creator><creator>MARTIN WIKBERG</creator><scope>EVB</scope></search><sort><creationdate>20090817</creationdate><title>Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine</title><author>BIRGITTA OLSSON ; JAN STROEMBOM ; BENGT HALLEN ; LISBETH NILVEBRANT ; ANDERS RINGBERG ; TORKEL GREN ; MARTIN WIKBERG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EE05191B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>est</language><creationdate>2009</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BIRGITTA OLSSON</creatorcontrib><creatorcontrib>JAN STROEMBOM</creatorcontrib><creatorcontrib>BENGT HALLEN</creatorcontrib><creatorcontrib>LISBETH NILVEBRANT</creatorcontrib><creatorcontrib>ANDERS RINGBERG</creatorcontrib><creatorcontrib>TORKEL GREN</creatorcontrib><creatorcontrib>MARTIN WIKBERG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BIRGITTA OLSSON</au><au>JAN STROEMBOM</au><au>BENGT HALLEN</au><au>LISBETH NILVEBRANT</au><au>ANDERS RINGBERG</au><au>TORKEL GREN</au><au>MARTIN WIKBERG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine</title><date>2009-08-17</date><risdate>2009</risdate><abstract>The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	est
recordid	cdi_epo_espacenet_EE05191B1
source	esp@cenet
subjects	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T11%3A45%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BIRGITTA%20OLSSON&rft.date=2009-08-17&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEE05191B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true